Dutch biopharmaceutical company Prosensa Therapeutics has appointed Larry Bell as head of global regulatory affairs.
He joins the Leiden-based company with more than 18 years of regulatory affairs experience gained at companies that include Merck, Bristol-Myers Squibb, Aventis and Amgen.
Prior to setting up his own consultancy, his most recent role was as vice president and global head of regulatory affairs at GE Healthcare
For his new role at Prosensa, which focuses on RNA-modulating therapeutics for rare diseases with high unmet need, Bell will be based in the US and oversee the company’s global regulatory activities.
Bell said: “This is a key time to be joining the Prosensa team. As the orphan drugs space grows in size and scope, there are many regulatory considerations that need to be addressed in order for new drugs to reach the patients that need them.
“I look forward to helping progress Prosensa’s cutting-edge therapies through the regulatory process.”